# Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)

> **NCT03948568** · PHASE4 · COMPLETED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 262 (actual)

## Conditions studied

- Early-stage Breast Cancer

## Interventions

- **COMBINATION_PRODUCT:** Endocrine Therapy and Radiotherapy

## Key facts

- **NCT ID:** NCT03948568
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-17
- **Primary completion:** 2021-06-09
- **Final completion:** 2022-04-09
- **Target enrollment:** 262 (ACTUAL)
- **Last updated:** 2022-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03948568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03948568, "Evaluating Optimal Timing of Endocrine Therapy and Radiation Therapy in Early-stage Breast Cancer (REaCT-RETT)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03948568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*